[{"document_url": "https://link.springer.com/article/10.1007%2Fs12094-010-0461-4", "unformatted_src": "https://static-content.springer.com/cover/journal/12094/12/1.jpg", "src": "https://static-content.springer.com/cover/journal/12094/12/1.jpg", "alt_text": "Clinical and Translational Oncology"}, null]
Clinical and Translational Oncology

January 2010, Volume 12, Issue 1, pp 15–21 | Cite as

Molecular basis for the treatment of renal cell carcinoma

Educational Series


Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.


Renal cell carcinoma Molecular basis Targeted therapies Key pathways





© Feseo 2010



Suárez, C., Morales, R., Muñoz, E. et al. Clin Transl Oncol (2010) 12: 15. https://doi.org/10.1007/s12094-010-0461-4





